New techniques can predict and prevent lung cancer

New Techniques Can Predict and Prevent Lung Cancer

New techniques can predict and prevent – Prevention of lung cancer has long relied on lifestyle changes, but recent advancements suggest a shift toward targeted interventions. A groundbreaking study reveals that existing anti-inflammatory drugs may offer a new pathway for both predicting and preventing the disease.

Lung cancer remains the leading cause of cancer diagnosis worldwide, even as smoking rates decline. Quitting smoking reduces immediate risks, yet former smokers still face a higher lifetime chance of developing the disease compared to lifelong non-smokers. Environmental factors, such as prolonged exposure to polluted air near busy London roads, also elevate risk.

Molecular Signature for Early Detection

An international collaboration of 80 researchers has discovered a molecular marker that can signal lung cancer risk years before symptoms appear. By analyzing blood samples from nearly 50,000 individuals stored in the UK Biobank, the team employed machine learning to identify 14 proteins whose levels rose significantly five years prior to diagnoses.

The signature was validated across eight global datasets, including a Taiwanese study where few participants smoked. These findings, published in Cell on June 4th, highlight a potential tool for early intervention.

Blocking Inflammation to Halt Cancer

Lab experiments on mice and human cells demonstrated that the 14 proteins accumulate when an inflammatory pathway tied to lung cancer becomes active. This pathway was first identified in 2023 by Charlie Swanton’s team at the Francis Crick Institute in London. They showed that air pollution triggers the release of interleukin-1 beta (IL-1ß), which activates dormant cancer mutations in lung cells, leading to tumor growth.

“Remarkably, blocking IL-1ß in mice exposed to air pollution prevented tumors from forming, suggesting a path for preventive drugs,” noted Dr. Swanton.

Current IL-1ß inhibitors are already used to manage autoimmune conditions like arthritis. Dr. Swanton’s team revisited data from a 2017 trial of canakinumab, an IL-1ß blocker, and found that participants treated with the drug had lower lung cancer rates than those on placebo. The benefit was most pronounced in individuals with elevated protein levels.

Efficient Prevention for High-Risk Groups

While the overall effect was modest, the 14-protein signature revealed striking differences. In high-risk groups, canakinumab nearly halved cancer incidence. For this subgroup, just 55 people would need treatment to prevent one case—a rate comparable to statins used for heart disease prevention.

Future research aims to create a commercial test for detecting the signature. Scientists are also exploring whether other anti-inflammatory medications could deliver similar results. Additional UK Biobank data, expected within two years, may uncover similar patterns for other cancers.

Meanwhile, ongoing trials in England suggest aspirin may prevent colorectal cancers in people with Lynch syndrome. This shift marks a turning point, as cancer prevention could finally receive the scientific focus once reserved for treatment innovation.